A Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Patients must be 18 years of age or greater.
- Histologically or cytologically proven non-small cell lung cancer that is either
metastatic or recurrent and failed at least one prior platinum-based chemotherapeutic
- Patients who have recurred after previous surgery and/or radiation may participate in
- Patients may have had prior neoadjuvant or adjuvant therapy.
- Patients with known brain metastases are eligible for this clinical trial if their
disease has been treated and they are clinically stable and documented by a stable or
improved pretreatment CT or MRI scan of the brain to evaluate for CNS disease within
28 days prior to registration.
- Measurable OR non-measurable disease documented by CT, MRI, X-ray or nuclear exam
(FDG-PET). Measurable or non-measurable disease must be present outside the area of
surgical resection. Pleural effusions, ascites and laboratory parameters are not
acceptable as the only evidence of disease.
- Progression after at least one prior platinum-based chemotherapy.
- Greater than 3 weeks since surgery and must have recovered from all associated
toxicities at time of registration.
- ANC ≥ 1,500/µl and platelet count ≥ 100,000/µl obtained within 28 days prior to
- Adequate hepatic function documented by a serum bilirubin ≤ 1.5 times institutional
upper limit of normal and liver enzymes (SGOT or SGPT) ≤ 2.5 x the institutional
upper limit of normal obtained within 28 days prior to registration.
- Patients requiring lung radiation must have an FEV1 of > 1000 liters obtained within
28 days prior to registration and must have pulmonary function tests with DLCO.
- Zubrod Performance Status of 0,1 or 2.
- No prior single-agent, weekly Docetaxel chemotherapy.
- Peripheral neuropathy ≥ Grade 1.
- Prior malignancy except for the following: adequately treated basal cell or squamous
cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer
from which the patient is currently in complete remission or other cancer from which
the patient has been disease-free for 5 years.
- Pregnant or nursing women.